Things like smoking, poor diet, and lack of exercise can increase a person’s risk of developing cancer, but there are some things that are actually more clinically acute outside of family history that every patient needs to look out for, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Things like smoking, poor diet, and lack of exercise can increase a person’s risk of developing cancer, but there are some things that are actually more clinically acute outside of family history that every patient needs to look out for, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
In addition to hereditary factors, what are common lifestyle factors that would put an individual at higher risk for developing certain cancers?
Some of the lifestyle related factors that increase a patient’s cancer risk are things like smoking, poor diet, lack of exercise, but there are some things that are actually more clinically acute outside of your family history that every patient needs to be looking out for. One of those is the number of biopsies that you’ve had when undergoing screening mammography, your breast density—that’s something that is a clear marker that increases your risk. It’s all of these things that go into a CancerIQ analysis so we know exactly what next steps a patient needs to take.
If you are in that higher risk category, the biggest risk factor for you is noncompliance. There are several women that may be okay skipping their annual mammogram and doing it every 2 years but there’s a certain portion of women who absolutely can not, and on top of their mammogram, they actually need to be getting an [magnetic resonance image] to increase the likelihood that we detect cancer early or prevent it altogether.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More